During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.
ONCT-534 reduced prostate-specific antigen levels in patients with relapsed/refractory metastatic castration-resistant prostate cancer.
The FDA has accepted and granted priority review to the new drug application for the glioma imaging agent TLX101-CDx.
Pembrolizumab-based combinations have been approved in Europe in 2 new indications for endometrial and cervical cancer.
Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of cytotoxic agents. The technology to develop these agents has improved in past…
Noman Ashraf, MD, discusses the evolving treatment landscape in non–small cell lung cancer following numerous regulatory approvals in the space.
Ariel Lopez-Chavez, MD, provides an overview of the most promising advancements in targeted therapies for the treatment of small cell lung cancer.
Jairam Krishnamurthy, MD, FACP, discusses factors that influence his choice between ribociclib and abemaciclib in the adjuvant breast cancer setting.
In this issue of Cancer Cell, MacFawn et al. reveal that tertiary lymphoid structures (TLSs) in high-grade serous ovarian cancer (HGSOC) vary significantly by anatomical site.…
